Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.
about
Drug-Induced Metabolic AcidosisClinical and economic aspects of sevelamer therapy in end-stage renal disease patients.Consequences and therapy of the metabolic acidosis of chronic kidney disease.Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis.Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic reviewManagement of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.Phosphate Binding with Sevelamer Preserves Mechanical Competence of Bone Despite Acidosis in Advanced Experimental Renal Insufficiency.The safety of phosphate binders.New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).Update and critical appraisal of sevelamer in the management of chronic renal failure.Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo.A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.Selecting an equation to estimate glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems.Correlation of coronary artery calcification with pre-hemodialysis bicarbonate levels in patients on hemodialysis.Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomerClinical experiences of bixalomer usage at our hospitalEffects of change in the formulation of lanthanum carbonate on laboratory parametersLanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patientsEvolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-upDeterminants of metabolic acidosis among hemodialysis patientsBicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxideIron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope 58Fe
P2860
Q26766204-70F38101-6B42-49F5-B60D-55BC1A7F42B4Q33610457-37E3B687-9BC7-40A8-B0DD-118CB4E75621Q34347210-6CF566B8-1FB5-4454-A53A-892CE2CC8003Q35002376-982F4802-7821-4099-8153-D4CCC5527E40Q35019709-705A6547-2DA1-44D6-AAFE-DC1B083D1DE4Q35026657-C2684C14-853D-4E7D-997D-1FF52F9EC236Q35876363-6EEFAB16-FE29-4505-A00E-C1AAB56A91EFQ36141100-FAAD9089-042E-4177-92FD-074BE0C666FBQ36565049-CCF162DC-437C-47FB-A255-E2BF11424DE0Q37111857-542AF8A3-1AC6-4A37-A3FC-74DAE86FE0B6Q37232307-5E39E08E-F40A-414F-A51A-36678217D83DQ37803240-FF53143B-68B7-4F23-BC9A-B241842FF938Q38160473-0F619708-F41D-4F18-B437-3DC0E1BAC7DAQ38892733-991867ED-B80F-4BE7-93F7-14337671F70DQ44167625-31EC447D-B670-48CE-8F57-6ADCAFB8D51CQ45015610-17733824-799A-40A9-874C-8E061510199EQ46520636-37E04446-B760-46B4-88B6-081F933829A0Q49146178-6623E806-9C19-40A1-BC4A-19B443CAEFCAQ57216468-E33B9132-5BFF-43A0-8B78-11017BE62AE3Q57217023-8BE22BDD-6557-4DFC-8044-99E8241C5BABQ57217030-C6265D24-E894-434D-BBE7-83729E4B5723Q57220069-D2716DA0-606F-4751-920C-259807E78438Q57221836-C356F345-DD99-4EFA-B4EE-AC5912E0D703Q57221999-F0887B87-156D-43F1-A500-A075FEFE8632Q57479316-EF1FBE8E-2522-4881-9C36-E6089FB26245Q57695687-67CCEE87-3322-4568-A042-5ED0D7D34E2F
P2860
Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Acid loading during treatment ...... sms and clinical implications.
@ast
Acid loading during treatment ...... sms and clinical implications.
@en
type
label
Acid loading during treatment ...... sms and clinical implications.
@ast
Acid loading during treatment ...... sms and clinical implications.
@en
prefLabel
Acid loading during treatment ...... sms and clinical implications.
@ast
Acid loading during treatment ...... sms and clinical implications.
@en
P2093
P1476
Acid loading during treatment ...... sms and clinical implications.
@en
P2093
Barton Brezina
Charles R Nolan
Wajeh Y Qunibi
P304
P356
10.1111/J.1523-1755.2004.09007.X
P577
2004-09-01T00:00:00Z